Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2021-10, Vol.23 (10), p.2269-2278
• Main Authors: Yale, Jean‐François, Catarig, Andrei‐Mircea, Grau, Katrine, Harris, Stewart, Klimek‐Abercrombie, Agnieszka, Rabasa‐Lhoret, Rémi, Reardon, Laura, Woo, Vincent, Liutkus, Joanne
• Format: Article
• Language: English
• Subjects: Antidiabetics; Body weight; Body weight loss; Clinical medicine; Diabetes; Diabetes mellitus (non-insulin dependent); Drug administration; Drug dosages; GLP-1 receptor agonists; GLP‐1RA; Glucagon; glycaemic control; Insulin; Observational studies; Original; Patients; routine clinical practice; semaglutide; SURE study; type 2 diabetes; Weight control
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14468

Aim To investigate once‐weekly (OW) semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) in routine clinical practice. Methods The SURE Canada study was a multicenter, prospective, observational study. Adults with T2D and one or more documented HbA1c values 12 weeks or less before semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included change in body weight (BW), waist circumference and patient‐reported outcomes (PROs) and the proportion of patients achieving HbA1c of less than 7.0%, weight loss (WL) of 5% or higher, and a composite of HbA1c reduction of 1% or higher and WL of 3% or higher at EOS. Data were analysed and presented for patients on semaglutide at EOS overall and for the following baseline medication subgroups: oral antihyperglycaemic drugs (OADs) only; GLP‐1RA experienced; insulin ± OADs without GLP‐1RA. Results In total, 452 patients initiated semaglutide and 356 completed the study on treatment. For the 452 patients, mean baseline HbA1c was 8.1%; 86 (19.0%) patients had HbA1c of less than 7.0%. Mean dose of semaglutide at EOS was 0.76 ± 0.31 mg. Mean HbA1c was reduced by 0.9%‐point (95% confidence interval [CI]: 0.97; 0.78). Mean BW was reduced by 4.3 kg (95% CI: 4.79; 3.76). At EOS, 46.9% of patients achieved HbA1c of less than 7.0%, 40.9% achieved WL of 5% or higher and 24.1% achieved the composite endpoint. PROs improved from baseline to EOS. No new safety concerns were reported. Conclusions In SURE Canada, patients treated with OW semaglutide in routine clinical practice experienced clinically significant improvements in HbA1c, BW and other outcomes, supporting semaglutide use in routine clinical practice.